TABLE.

Baseline Patient Characteristics^a,b

	Group A (LVEDV <200 mL) (n=72)	Group B (LVEDV 200–370 mL) (n=54)	P
Age, y	52±11	53±10	.95
Male sex	57 (79)	45 (83)	.55
BMI, kg/m2	24.7±4.1	25.8±3.5	.60
DCM etiology
History of viral infection	55 (76)	43 (80)	.67
Familial	3 (4)	3 (6)
Idiopathic	14 (19)	8 (15)
Creatinine, mg/dL	1.07±0.28	1.03±0.21	.2l
Bilirubin, mg/dL	0.98±0.55	1.00±0.51	.58
Hemoglobin, g/dL	13.5 ± 1.2	13.2±1.1	.2l
Sodium, mmol/L	138±7	137±6	.62
NT-proBNP, pg/mL	1454±1658	1589±1338	.80
LVEF, %	32.8±8.7	30.2±8.6	.03
Significant FMR	60 (83)	52 (96)	.02
6-minute walk, m	355±87	345±92	.72
Drug therapy
ACEI/ARB	70 (97)	53 (98)	.74
Beta blockers	64 (89)	50 (93)	.48
MRA	55 (76)	45 (83)	.34
Digoxin	10 (14)	6 (11)	.64
Loop diuretics	68 (94)	52 (96)	.63

^aACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; DCM = dilated cardiomyopathy; FMR = functional mitral regurgitation; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NT-pro BNP = N-terminal probrain natriuretic peptide.

^bValues are presented as mean SD or n (%).